We are live on
!
Find out more
VA
Verdad Advisers Portfolio holdings
AUM
$104M
This Fund
S&P 500
This Quarter
Est. Return
+21.07%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
+$15.6M
(+18%)
Cap. Flow
+$3.28M
Cap. Flow
% of AUM
3.14%
Top 10 Holdings %
Top 10 Hldgs %
18.12%
Holding
276
New
97
Increased
59
Reduced
42
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.13M |
| 2 |
Protara Therapeutics
TARA
|
+$1.49M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$1.44M |
| 4 |
Tyra Biosciences
TYRA
|
+$1.19M |
| 5 |
JBIO
Jade Biosciences
JBIO
|
+$1.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$2.57M |
| 2 |
Revolution Medicines
RVMD
|
+$2.56M |
| 3 |
State Street
STT
|
+$2.11M |
| 4 |
Autohome
ATHM
|
+$2.11M |
| 5 |
Cal-Maine
CALM
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.7% |
| 2 | Technology | 15.71% |
| 3 | Financials | 9.07% |
| 4 | Communication Services | 7.06% |
| 5 | Consumer Discretionary | 5.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Tactile Systems Technology
TCMD
$499M
| $271K | 0.26% |
9,115
+1,299
| +17% | +$32.6K |
|
127
Bread Financial
BFH
$4.18B
| $271K | 0.26% |
+2,503
| New | +$225K |
|
|
INGM
128
Ingram Micro Holding
INGM
$6.6B
| $261K | 0.25% |
+9,499
| New | +$267K |
|
129
Foghorn Therapeutics
FHTX
$293M
| $260K | 0.25% |
53,231
+28,815
| +118% | +$128K |
|
130
Lincoln Educational Services
LINC
$808M
| $259K | 0.25% |
5,200
-134
| -3% | -$6.07K |
|
|
FINV
131
FinVolution Group
FINV
$781M
| $257K | 0.25% |
53,699
+38,554
| +255% | +$191K |
|
|
MBX
132
MBX Biosciences
MBX
$2.94B
| $252K | 0.24% |
+4,574
| New | +$160K |
|
133
Perdoceo Education
PRDO
$2.05B
| $250K | 0.24% |
7,797
-1,153
| -13% | -$39.5K |
|
134
BK Technologies
BKTI
$277M
| $242K | 0.23% |
2,814
+86
| +3% | +$7.46K |
|
135
Federated Hermes
FHI
$4.59B
| $240K | 0.23% |
4,355
-9,355
| -68% | -$529K |
|
136
AnaptysBio
ANAB
$1.71B
| $236K | 0.23% |
+3,498
| New | +$212K |
|
137
TScan Therapeutics
TCRX
$25M
| $228K | 0.22% |
232,759
+98,758
| +74% | +$105K |
|
|
NRT
138
North European Oil Royalty Trust
NRT
$82.7M
| $225K | 0.22% |
30,782
| – | – |
|
139
Macy's
M
$5.93B
| $224K | 0.22% |
9,532
-16,071
| -63% | -$336K |
|
140
Johnson Outdoors
JOUT
$476M
| $224K | 0.21% |
+4,869
| New | +$231K |
|
|
SLN
141
Silence Therapeutics
SLN
$910M
| $224K | 0.21% |
+20,400
| New | +$144K |
|
|
LBRX
142
LB Pharmaceuticals
LBRX
$1.56B
| $223K | 0.21% |
+6,867
| New | +$202K |
|
143
Cogent Biosciences
COGT
$6.05B
| $221K | 0.21% |
5,705
+376
| +7% | +$13.2K |
|
144
Photronics
PLAB
$1.7B
| $220K | 0.21% |
+6,775
| New | +$287K |
|
145
FIGS
FIGS
$2.49B
| $220K | 0.21% |
21,483
-2,768
| -11% | -$36.4K |
|
146
Adicet Bio
ACET
$89.2M
| $218K | 0.21% |
+25,200
| New | +$199K |
|
|
BCYC
147
Bicycle Therapeutics
BCYC
$298M
| $217K | 0.21% |
+51,100
| New | +$234K |
|
148
Myriad Genetics
MYGN
$303M
| $214K | 0.21% |
+37,500
| New | +$170K |
|
149
Sutro Biopharma
STRO
$333M
| $212K | 0.2% |
+6,400
| New | +$200K |
|
150
Palisade Bio
PALI
$359M
| $208K | 0.2% |
+99,660
| New | +$196K |
|
Similar funds
IAP
JRSI
SFG
TPW
ACM
TOTUOP
XFP
ICVCFVA
Verdad Advisers's Q2 2026 Portfolio in Review
As of Q2 2026, Verdad Advisers held 276 positions worth $104M, up 18% from $88.8M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Verdad Advisers deployed $3.28M of net new capital in Q2 2026, opening 97 new positions and adding to 59 existing holdings. Its largest new stake was Apple: 7,445 shares worth $2.15M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 42% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Micron Technology, an estimated $2.57M trimmed.
- Verdad Advisers's largest Q2 2026 buy was Apple: 7,445 shares worth $2.15M.
- Verdad Advisers added most to Comcast in Q2 2026, an estimated $1.11M increase.
- Verdad Advisers's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $2.57M.
- Verdad Advisers fully exited State Street in Q2 2026, selling an estimated $2.11M.
- Verdad Advisers's ten largest holdings make up 18% of its $104M portfolio in Q2 2026.
- Verdad Advisers opened 97 new positions and closed 66 in Q2 2026.
- Verdad Advisers's portfolio value rose 18% quarter-over-quarter to $104M.
Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.